Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11520 posts found.

merck-keytruda

NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

October 22, 2020 Sales and Marketing MSD, NCIE, NHS, keytruda

NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment …
News
astrazeneca-sign

FDA grants priority review to AstraZeneca’s Tagrisso as an adjuvant for early-stage EGFR-mutated non-small cell lung cancer

October 20, 2020 Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Tagrisso

The FDA has revealed its decision to grant Priority Review to AstraZeneca’s Tagrisso (osimertinib) as an adjuvant treatment of patients …
News
shutterstock_3

EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma

October 20, 2020 Manufacturing and Production, Sales and Marketing CAR T, CAR-T, CHMP, EMA, kite pharma, lymphoma

Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received positive recommendation from the EMA’s …
News
eu_member_flags

European Commission stands by €1bn remdesivir supply deal despite disappointing COVID-19 benefit

October 19, 2020 Manufacturing and Production, Sales and Marketing COVID-19, Europe, Gilead, remdesivir

As Europe continues to face down a rising second wave of COVID-19, the European Commission quickly moved to secure a …
News

Pfizer won’t apply for COVID-19 vaccine emergency authorisation until after US election, CEO says

October 19, 2020 Sales and Marketing COVID-19, Pfizer, US, Vaccine

The Chief Executive Officer of Pfizer has said that the company will now submit their vaccine for FDA Emergency Use …
News
brexit-hintergrund_web

UK life sciences industry does not want no-deal Brexit, says ABPI Chief

October 19, 2020 Sales and Marketing ABPI, EU, UK, brexit, pharma

Prime Minister Boris Johnson’s sudden change of position that the UK is now expecting a no-deal scenario with the European …
News
sanofi_hq__boetie_hall_web

Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis

October 19, 2020 Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis

Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …
News
janssen_latest_logo_on_sign

CHMP recommendation for Janssen’s Tremfya in active psoriatic arthritis

October 19, 2020 Sales and Marketing CHMP, EMA, Janssen, Tremfya

Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) has scored a recommendation from the EMA’s Committee for Medicinal Products for Human Use …
News

FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal

October 19, 2020 Sales and Marketing AbbVie, FDA, Roche, Venclexta, pharma

The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose …
News
nice_new_london_office_internal_3_web

NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma

October 16, 2020 Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …
News
piccadilly_circus_station_during_london_covid-19_lockdown

80 researchers argue COVID-19 herd immunity strategy is a “dangerous fallacy” in open letter

October 15, 2020 Medical Communications, Research and Development, Sales and Marketing COVID-19

A group of 80 researchers have lent their signatures to an open letter published in the The Lancet under the …
News

Scottish Medicines Consortium gives go-ahead for Novartis’ Mayzent in secondary progressive multiple sclerosis

October 15, 2020 Sales and Marketing Mayzent, Novartis, Scotland

Novartis’ Mayzent (siponimod) has been approved by the Scottish Medicines Consortium in the treatment of secondary progressive multiple sclerosis (SPMS) …
News
shutterstock_512649

Johnson & Johnson to contribute a further $1 billion to US opioid settlement

October 14, 2020 Research and Development, Sales and Marketing J&J, JJ, opioid crisis, opioids, pharma

Johnson & Johnson will pay another $1 billion to settle lawsuits alleging it fuelled the opioid crisis in the US. …
News
bavencio

Bavencio/axitinib combo approved for NHS Scotland in advanced renal cell carcinoma

October 13, 2020 Manufacturing and Production, Sales and Marketing Merck, NHS, Pfizer, SMC

The Scottish Medicines Consortium (SMC) has given the go-ahead to Merck KGaA and Pfizer’s combination of their PD-L1 inhibitor immunotherapy …
News
shutterstock_3

University of Glasgow research details promising precision medicine approach in pancreatic cancer

October 12, 2020 Research and Development, Sales and Marketing Cancer, Precision Medicine

Researchers at the University of Glasgow have unveiled a new precision medicine approach to identify and pair pancreatic cancer patients …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025